A Single-Institute Experience with Sorafenib in Untreated and Previously Treated Patients with Advanced Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|78|3-4|210-212

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.3-4, 2010-04, pp. : 210-212

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models

By  

Oncology, Vol. 80, Iss. 3-4, 2011-06 ,pp. : 167-174

Karger

Access to resources Recommend Favorite

Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric

By  

Oncology, Vol. 67, Iss. 1, 2004-10 ,pp. : 27-32

Karger

Access to resources Recommend Favorite

Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 192-200

Karger

Access to resources Recommend Favorite

Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series

By  

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 265-272

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite